Caricamento...
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer’s disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies. An additional phase III trial is ongoing...
Salvato in:
| Pubblicato in: | J Neuroinflammation |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265363/ https://ncbi.nlm.nih.gov/pubmed/25476011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-014-0198-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|